SCHEMBL5746151

SCHEMBL5746151

N#Cc1ccccc1N1CCN(S(=O)(=O)c2cccc(CC(=O)O)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
ATM Q13315 1/20 0.50
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 1/20 0.45
MCOLN3 Q8TDD5 1/20 0.45
PTPN11 Q06124 2/20 0.45
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5749033 0.86 HDAC3 (0.56) ALDH1A1SMN1; SMN2LMNAMCOLN3PTPN11
SCHEMBL5799614 0.84 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2LMNAPTPN11HDAC3
SCHEMBL6357532 0.83 HTT (0.58) ALDH1A1SMN1; SMN2LMNAPTPN11HDAC3
SCHEMBL5746692 0.83 TNF (0.54) L3MBTL1ALDH1A1SMN1; SMN2LMNAPTPN11
SCHEMBL5776077 0.82 GFER (0.45) L3MBTL1ALDH1A1SMN1; SMN2LMNAMCOLN3
SCHEMBL5747349 0.82 GAA (0.69) ALDH1A1SMN1; SMN2LMNAHDAC3HDAC4
SCHEMBL5747135 0.80 GAA (0.63) ALDH1A1SMN1; SMN2LMNAMCOLN3DRD2
SCHEMBL5748086 0.79 MAPT (0.58) L3MBTL1ALDH1A1SMN1; SMN2LMNAMCOLN3
SCHEMBL5772886 0.79 LMNA (0.69) L3MBTL1SMN1; SMN2LMNAMCOLN3KDM4E
SCHEMBL13804969 0.78 POLB (0.59) SMN1; SMN2LMNAGAATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD L3MBTL1 4277/4885ATM 2262/4885ALDH1A1 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.